Benzinga·2026-02-12 18:02Group 1: Company Strategy and Product Development - Novo Nordisk plans to start selling its obesity drug Wegovy in vials, aiming to strengthen its market position against Eli Lilly as competition in the weight-loss market intensifies [1] - The introduction of vials is part of Novo Nordisk's broader ambition to reach millions of people living with obesity, offering more flexible dosing options compared to prefilled pens [3] - Novo Nordisk is evaluating multiple device configurations for Wegovy, with some expected to launch this year and others at a later stage [3] Group 2: Market Competition and Performance - Eli Lilly's CEO stated that vials have become the most popular format for weight-loss therapy, accounting for roughly one-third of new patients starting any therapy [2] - Novo Nordisk has not disclosed pricing details for its vial format and plans to introduce vials in the U.S. first before expanding to other markets [2] - Novo Nordisk expects adjusted sales growth for 2026 to be -5% to -13% at constant exchange rates, attributed to lower realized prices and increased competition [4] Group 3: Legal and Stock Performance - Novo Nordisk filed a lawsuit against Hims & Hers earlier this week [5] - As of the publication date, Novo Nordisk's stock is down 0.82% at $48.34 [5]